Kuzumaki N - Search Results

1

Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Ras mutant, N116Y.

Senmaru N, Shichinohe T, Takeuchi M, Miyamoto M, Sazawa A, Ogiso Y, Takahashi T, Okushiba S, Takimoto M, Kato H, Kuzumaki N. Senmaru N, et al. Among authors: kuzumaki n. Int J Cancer. 1998 Oct 29;78(3):366-71. doi: 10.1002/(SICI)1097-0215(19981029)78:3<366::AID-IJC18>3.0.CO;2-4. Int J Cancer. 1998. PMID: 9766573 Free article.

2

Suppression of various human tumor cell lines by a dominant negative H-ras mutant.

Ogiso Y, Sakai N, Watari H, Yokoyama T, Kuzumaki N. Ogiso Y, et al. Among authors: kuzumaki n. Gene Ther. 1994 Nov;1(6):403-7. Gene Ther. 1994. PMID: 7584106

3

Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y.

Shichinohe T, Senmaru N, Furuuchi K, Ogiso Y, Ishikura H, Yoshiki T, Takahashi T, Kato H, Kuzumaki N. Shichinohe T, et al. Among authors: kuzumaki n. J Surg Res. 1996 Dec;66(2):125-30. doi: 10.1006/jsre.1996.0383. J Surg Res. 1996. PMID: 9024823

4

Involvement of Ras in the expression of glycolipid sulfotransferase in human renal cancer cells.

Yabunaka N, Honke K, Ishii A, Ogiso Y, Kuzumaki N, Agishi Y, Makita A. Yabunaka N, et al. Among authors: kuzumaki n. Int J Cancer. 1997 May 16;71(4):620-3. doi: 10.1002/(sici)1097-0215(19970516)71:4<620::aid-ijc18>3.0.co;2-f. Int J Cancer. 1997. PMID: 9178817

5

Suppressive effects of dominant negative ras mutant N116Y on transformed phenotypes of human bladder cancer cells.

Watanabe T, Shinohara N, Sazawa A, Kobayashi Y, Ogiso Y, Kimura T, Takiguchi M, Yasuda J, Hashimoto A, Koyanagi T, Kuzumaki N. Watanabe T, et al. Among authors: kuzumaki n. Cancer Lett. 2000 Feb 28;149(1-2):195-202. doi: 10.1016/s0304-3835(99)00359-6. Cancer Lett. 2000. PMID: 10737724

6

The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice.

Takeuchi M, Shichinohe T, Senmaru N, Miyamoto M, Fujita H, Takimoto M, Kondo S, Katoh H, Kuzumaki N. Takeuchi M, et al. Among authors: kuzumaki n. Gene Ther. 2000 Mar;7(6):518-26. doi: 10.1038/sj.gt.3301125. Gene Ther. 2000. PMID: 10757026

7

Adenovirus-mediated gene therapy for bladder cancer in an orthotopic model using a dominant negative H-ras mutant.

Watanabe T, Shinohara N, Sazawa A, Takimoto M, Hashimoto A, Koyanagi T, Kuzumaki N. Watanabe T, et al. Among authors: kuzumaki n. Int J Cancer. 2001 Jun 1;92(5):712-7. doi: 10.1002/1097-0215(20010601)92:5<712::aid-ijc1242>3.0.co;2-z. Int J Cancer. 2001. PMID: 11340577

8

Gelsolin gene silencing involving unusual hypersensitivities to dimethylsulfate and KMnO4 in vivo footprinting on its promoter region.

Haga K, Fujita H, Nomoto M, Sazawa A, Nakagawa K, Harabayashi T, Shinohara N, Takimoto M, Nonomura K, Kuzumaki N. Haga K, et al. Among authors: kuzumaki n. Int J Cancer. 2004 Oct 10;111(6):873-80. doi: 10.1002/ijc.20348. Int J Cancer. 2004. PMID: 15300799 Free article.

9

siRNA gelsolin knockdown induces epithelial-mesenchymal transition with a cadherin switch in human mammary epithelial cells.

Tanaka H, Shirkoohi R, Nakagawa K, Qiao H, Fujita H, Okada F, Hamada J, Kuzumaki S, Takimoto M, Kuzumaki N. Tanaka H, et al. Among authors: kuzumaki s, kuzumaki n. Int J Cancer. 2006 Apr 1;118(7):1680-91. doi: 10.1002/ijc.21559. Int J Cancer. 2006. PMID: 16217750 Free article.

10

Resistance to oncogenic transformation in revertant R1 of human ras-transformed NIH 3T3 cells.

Kuzumaki N, Ogiso Y, Oda A, Fujita H, Suzuki H, Sato C, Müllauer L. Kuzumaki N, et al. Mol Cell Biol. 1989 May;9(5):2258-63. doi: 10.1128/mcb.9.5.2258-2263.1989. Mol Cell Biol. 1989. PMID: 2664473 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

226 results

Search Page

Filters